Smith Jason Drew
SEC CIK 1821479 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| URGN | UroGen Pharma Ltd. | GC | 53.1K | — | $804.3K | 25 | 2021-11-30 | 2026-09-08 |
Most active insiders at URGN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schoenberg Mark | Chief Medical Off | — | $4.48M |
| 2 | Smith Jason Drew | GC | — | $211.9K |
| 3 | Degnan Chris | CFO | — | $37.1K |
| 4 | Wildman Daniel George | Dir | — | — |
| 5 | WEN LEANA | Dir | — | — |
| 6 | Holden Stuart | Dir | — | — |
| 7 | Robinson James A. Jr. | Dir | — | — |
| 8 | BUTITTA CYNTHIA M | Dir | — | — |
Transactions 25
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-09 14:35 | 2026-09-07 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +3,334 | 54.7K | +6% | — |
| D | 2026-09-09 14:35 | 2026-09-08 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $42.54 | -1,519 | 53.1K | -3% | -$64.6K |
| DM | 2026-02-11 | 2026-01-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +15.5K | 55.5K | +39% | — |
| DM | 2026-02-11 | 2026-02-03 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $19.69 | -7,479 | 52.9K | -12% | -$147.3K |
| D | 2025-09-09 | 2025-09-08 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $19.11 | -1,520 | 43.3K | -3% | -$29.0K |
| D | 2025-09-09 | 2025-09-07 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +3,333 | 44.8K | +8% | — |
| 2025-07-30 | 2025-07-28 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $19.14 | -7,522 | 41.5K | -15% | -$144.0K | |
| 2025-07-30 | 2025-07-28 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +16.5K | 49.0K | +51% | — | |
| DM | 2025-02-04 | 2025-01-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $11.14 | -7,379 | 29.8K | -20% | -$82.2K |
| DM | 2025-02-04 | 2025-01-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +14.7K | 35.3K | +71% | — |
| D | 2024-09-12 | 2024-09-09 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +3,333 | 26.7K | +14% | — |
| D | 2024-09-12 | 2024-09-09 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $13.08 | -1,521 | 25.2K | -6% | -$19.9K |
| MA | 2024-02-05 | 2024-02-01 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale | $15.78 | -4,993 | 20.1K | -20% | -$78.8K |
| DM | 2024-02-02 | 2024-01-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +10.0K | 21.3K | +88% | — |
| DM | 2024-02-02 | 2024-01-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $15.74 | -4,993 | 20.1K | -20% | -$78.6K |
| D | 2023-09-05 | 2023-08-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $18.01 | -3,800 | 18.4K | -17% | -$68.4K |
| D | 2023-09-05 | 2023-08-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +8,334 | 22.2K | +60% | — |
| DM | 2023-02-02 | 2023-01-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $10.12 | -1,636 | 13.9K | -11% | -$16.6K |
| DM | 2023-02-02 | 2023-01-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +3,333 | 13.0K | +34% | — |
| D | 2022-09-02 | 2022-08-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $7.21 | -3,606 | 12.2K | -23% | -$26.0K |
| D | 2022-09-02 | 2022-08-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +8,333 | 15.8K | +112% | — |
| D | 2022-02-02 | 2022-01-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +833 | 7,863 | +12% | — |
| D | 2022-02-02 | 2022-01-31 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $7.58 | -414 | 7,449 | -5% | -$3,138 |
| D | 2021-12-02 | 2021-11-30 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | M - OptEx | — | +8,333 | 10.8K | +333% | — |
| D | 2021-12-02 | 2021-11-30 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $12.03 | -3,803 | 7,030 | -35% | -$45.8K |
Purchase Sale Sale after option exercise All abbreviations